{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T09:42:48Z","timestamp":1770457368262,"version":"3.49.0"},"reference-count":46,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"7","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1200\/op.21.00210","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T15:59:34Z","timestamp":1623340774000},"page":"415-418","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":4,"title":["Evolving Paradigms of Therapy for Multiple Myeloma: State of the Art and Future Directions"],"prefix":"10.1200","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9216-2418","authenticated-orcid":false,"given":"Scott R.","family":"Goldsmith","sequence":"first","affiliation":[{"name":"Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8795-3610","authenticated-orcid":false,"given":"Ravi","family":"Vij","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.21.00032"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31594-X"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0311-8"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26074"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-395749"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_238527"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30578-8"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.5032"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.675.675"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136907"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.18_suppl.LBA3"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005288"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15261"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31240-1"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32956-3"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4338"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114138"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114083"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30687-9"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.6679"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408898"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.335"},{"key":"e_1_3_6_26_2","first-page":"4533","article-title":"High rate of sustained minimal residual disease negativity predicts prolonged survival for the overall patient population in the phase 2 KRd plus autologous stem cell transplantation MMRC trial","volume":"130","author":"Jakubowiak AJ","year":"2017","unstructured":"Jakubowiak AJ, Raje N, Vij R, et al: High rate of sustained minimal residual disease negativity predicts prolonged survival for the overall patient population in the phase 2 KRd plus autologous stem cell transplantation MMRC trial. Blood 130:4533, 2017","journal-title":"Blood"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)33003-4"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-785246"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30734-0"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805762"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.15_suppl.tps8113"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-360552"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70380-2"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16213"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-863829"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-481325"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32556-5"},{"key":"e_1_3_6_41_2","article-title":"Isatuximab plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in relapsed\/refractory multiple myeloma (IKEMA): Interim analysis of a phase 3, randomized, open-label study","author":"Moreau P","year":"2020","unstructured":"Moreau P, Dimopoulos MA, Mikhael J, et al: Isatuximab plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in relapsed\/refractory multiple myeloma (IKEMA): Interim analysis of a phase 3, randomized, open-label study. Am Soc Hematol, 2020","journal-title":"Am Soc Hematol"},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903455"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32292-3"},{"key":"e_1_3_6_45_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02259"},{"key":"e_1_3_6_46_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124298"},{"key":"e_1_3_6_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30525-8"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP.21.00210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T18:37:03Z","timestamp":1752604623000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP.21.00210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1200\/OP.21.00210"],"URL":"https:\/\/doi.org\/10.1200\/op.21.00210","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"2021-03-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}